News

LUMIFY eye drops were initially introduced by Bausch + Lomb in 2018 and remain the only OTC redness relievers that selectively target eye redness with a lower risk of rebound redness and loss of efficacy when used as directed.

At ARVO 2025, in Salt Lake City, Utah, David Almeida, MD, MBA, PhD, talked about 12-month results from the PAVIA phase 2 trial of EYP-1901 in nonproliferative diabetic retinopathy.

Kapil Mishra, MD, discusses his presentation title "Radiation Retinopathy: Future Strategies" given at the 2025 Retina World Congress meeting.

At ARVO 2025, in Salt Lake City, Utah, Danielle Gauthier talked about her poster on autosomal dominant Alzheimer disease in relation to optic nerve head drusen.

At ARVO 2025, in Salt Lake City, Utah, Roger Goldberg, MD, MBA, talked about his presentation on the effect of AREDS vitamins in geographic atrophy.

Viridian Therapeutics reveals promising long-term results for veligrotug in treating thyroid eye disease, highlighting its potential as a leading therapy.

Recent study data reveal a significant rise in childhood astigmatism linked to the COVID-19 pandemic, independent of myopia.

At ARVO 2025, in Salt Lake City, Utah, Viha Vig, talked about her poster presentation investigating the relationship between ocular and systemic mitochondrial diseases and dementia

Ashvattha Therapeutics reveals promising phase 2 results for migaldendranib, showcasing significant improvements in retinal disease treatment and reduced injection burden.

Financing will fund phase 1b trials evaluating its lead candidate, THN391, for the treatment of Alzheimer disease and diabetic macular edema (DME).

SYL1801 is an investigational siRNA therapy administered via eye drops, rather than intravitreal injection, to treat nAMD.

At ARVO 2025, in Salt Lake City, Utah, Ferhina Ali, MD, MPH, talked about her presentation on the early real-world use of aflibercept 8 mg in treatment-naive patients with neovascular age-related macular degeneration

By making these retinal pigment epithelium (RPE) cells visible, researchers have created implications for early detection of disease and the monitoring of treatment response.

Shifting from a regulatory role to driving innovation directly, Eydelman discusses how the Collaborative Community on Ophthalmic Innovation is reshaping the field, streamlining outdated processes, and advancing patient-centered solutions worldwide.

At ARVO 2025, in Salt Lake City, Utah, C Michael Samson, MD, MBA, gave insight into his data on immune cell profiling in birdshot retinochoroidopathy using single-cell RNA sequencing.

The bill, which passed on May 1, allows for West Virginian ODs to provide certain in-office procedures such as laser treatments

A machine learning model incorporating treated astigmatism and nuanced inputs is advancing the precision and personalization of arcuate keratotomy planning

Rishi Singh, MD, discusses faricimab's real-world effectiveness in treating diabetic macular edema, highlighting improved vision and reduced treatment frequency.

AAVantgarde Bio reveals promising safety and efficacy data for AAV-based therapies targeting Usher syndrome and Stargardt disease at ARVO 2025.

LumiThera's Valeda system offers groundbreaking non-invasive treatment for dry AMD, showing extended vision improvement and safety over 4.5 years.

NCX 470, Nicox’s lead clinical product candidate, is a novel NO-donating bimatoprost eye drop with a dual mechanism of action (nitric oxide and prostaglandin analogue).

A recent analysis reveals a strong link between photoreceptor health and visual function in geographic atrophy, emphasizing the importance of EZ integrity.

Palatin Technologies reveals groundbreaking preclinical results on melanocortin agonists, showcasing their potential to combat diabetic retinopathy and preserve vision.

At ARVO 2025, in Salt Lake City, Utah, Diana Do, MD, gave an update on the LIGHTSITE III study of photobiomodulation for dry age-related macular degeneration.

Giullia Coradetti, MD, offered insight into her research on a post-hoc analysis based on the GATHER 2 clinical trial data for geographic atrophy and age-related macular degeneration.